1. Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, et al. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19. J Korean Med Sci. 2020; 35(13):e142. PMID:
32242348.
Article
2. Suh HJ, Kim DH, Heo EY, Lee HW, Lee JK, Lee CS, et al. Clinical characteristics of COVID-19: clinical dynamics of mild severe acute respiratory syndrome coronavirus 2 infection detected by early active surveillance. J Korean Med Sci. 2020; 35(32):e297. PMID:
32808513.
Article
3. Kim PS, Read SW, Fauci AS. Therapy for early COVID-19: a critical need. JAMA. 2020; 324(21):2149–2150. PMID:
33175121.
4. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, January 28, 2020. Accessed April 25, 2023.
https://apps.who.int/iris/handle/10665/330893
.
7. The National Institute for Health and Care Excellence (NICE) guideline: COVID-19 rapid guideline: managing COVID-19, March 23, 2021. Accessed April 25, 2023.
https://www.nice.org.uk/guidance/ng191
.
8. Jeon J, Chin B. Treatment options for patients with mild-to-moderate coronavirus disease 2019 in Korea. J Korean Med Sci. 2022; 37(48):e352. PMID:
36513054.
Article
9. Park DH, Kang CK, Choe PG, Kim NJ, Park WB, Oh MD. How we have treated severe to critically ill patients with coronavirus disease 2019 in Korea. J Korean Med Sci. 2022; 37(49):e353. PMID:
36536547.
Article
10. WHO Solidarity Trial Consortium. Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med. 2021; 384(6):497–511. PMID:
33264556.
Article
12. Kang CK, Seong MW, Choi SJ, Kim TS, Choe PG, Song SH, et al. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses. Korean J Intern Med. 2020; 35(4):782–787. PMID:
32460458.
Article
13. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020; 382(19):1787–1799. PMID:
32187464.
14. Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020; 586(7827):113–119. PMID:
32707573.
Article
15. Weston S, Coleman CM, Haupt R, Logue J, Matthews K, Li Y, et al. Broad anti-coronavirus activity of food and drug administration-approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo. J Virol. 2020; 94(21):e01218-20. PMID:
32817221.
Article
16. Berendes S, Heywood P, Oliver S, Garner P. Quality of private and public ambulatory health care in low and middle income countries: systematic review of comparative studies. PLoS Med. 2011; 8(4):e1000433. PMID:
21532746.
Article
17. Basu S, Andrews J, Kishore S, Panjabi R, Stuckler D. Comparative performance of private and public healthcare systems in low- and middle-income countries: a systematic review. PLoS Med. 2012; 9(6):e1001244. PMID:
22723748.
Article
18. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395(10223):473–475. PMID:
32043983.
19. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020; 395(10225):683–684. PMID:
32122468.
Article
20. RECOVERY Collaborative Group. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384(8):693–704. PMID:
32678530.
Article
23. Watanabe JH, Kwon J, Nan B, Abeles SR, Jia S, Mehta SR. Medication use patterns in hospitalized patients with COVID-19 in California during the pandemic. JAMA Netw Open. 2021; 4(5):e2110775. PMID:
34019090.
24. Nori P, Bartash R, Cowman K, Dackis M, Pirofski LA. Is burnout infectious? Understanding drivers of burnout and job satisfaction among academic infectious diseases physicians. Open Forum Infect Dis. 2019; 6(4):ofz092. PMID:
31041336.
Article
25. Lugtenberg M, Zegers-van Schaick JM, Westert GP, Burgers JS. Why don’t physicians adhere to guideline recommendations in practice? An analysis of barriers among Dutch general practitioners. Implement Sci. 2009; 4(1):54. PMID:
19674440.
Article
26. Lugtenberg M, Burgers JS, Han D, Westert GP. General practitioners’ preferences for interventions to improve guideline adherence. J Eval Clin Pract. 2014; 20(6):820–826. PMID:
24953439.
Article